Daniela Haase1, Laura Bäz1, Marcus Franz1, P Christian Schulze2, Tarek Bekfani1, Sophie Neugebauer3, Michael Kiehntopf3, Sven Möbius-Winkler1. 1. Division of Cardiology, Angiology, Pneumology and Intensive Medical Care, Department of Internal Medicine I, University Hospital Jena, Friedrich-Schiller-University, Jena, Germany. 2. Division of Cardiology, Angiology, Pneumology and Intensive Medical Care, Department of Internal Medicine I, University Hospital Jena, Friedrich-Schiller-University, Jena, Germany. christian.schulze@med.uni-jena.de. 3. Department of Clinical Chemistry and Laboratory Diagnostics, University Hospital Jena, Friedrich-Schiller-University, Jena, Germany.
Abstract
AIM: Aim of our study was to evaluate metabolic changes in patients with aortic stenosis (AS) before and after transcatheter aortic valve replacement (TAVR) and to assess whether this procedure reverses metabolomic alterations. METHODS: 188 plasma metabolites of 30 patients with severe high-gradient aortic valve stenosis (pre-TAVR and 6 weeks post-TAVR) as well as 20 healthy controls (HC) were quantified by liquid chromatography tandem mass spectrometry. Significantly altered metabolites were then correlated to an extensive patient database of clinical parameters at the time of measurement. RESULTS: Out of the determined metabolites, 26.6% (n = 50) were significantly altered in patients with AS pre-TAVR compared to HC. In detail, 5/40 acylcarnitines as well as 10/42 amino acids and biogenic amines were mainly increased in AS, whereas 29/90 glycerophospholipids and 6/15 sphingomyelins were mainly reduced. In the post-TAVR group, 10.1% (n = 19) of metabolites showed significant differences when compared to pre-TAVR. Moreover, we found nine metabolites revealing reversible concentration levels. Correlation with clinically important parameters revealed strong correlations between sphingomyelins and cholesterol (r = 0.847), acylcarnitines and brain natriuretic peptide (r = 0.664) and showed correlation of acylcarnitine with an improvement of left ventricular (LV) ejection fraction (r = - 0.513) and phosphatidylcholines with an improvement of LV mass (r = - 0.637). CONCLUSION: Metabolic profiling identified significant and reversible changes in circulating metabolites of patients with AS. The correlation of circulating metabolites with clinical parameters supports the use of these data to identify novel diagnostic as well as prognostic markers for disease screening, pathophysiological studies as well as patient surveillance.
AIM: Aim of our study was to evaluate metabolic changes in patients with aortic stenosis (AS) before and after transcatheter aortic valve replacement (TAVR) and to assess whether this procedure reverses metabolomic alterations. METHODS: 188 plasma metabolites of 30 patients with severe high-gradient aortic valve stenosis (pre-TAVR and 6 weeks post-TAVR) as well as 20 healthy controls (HC) were quantified by liquid chromatography tandem mass spectrometry. Significantly altered metabolites were then correlated to an extensive patient database of clinical parameters at the time of measurement. RESULTS: Out of the determined metabolites, 26.6% (n = 50) were significantly altered in patients with AS pre-TAVR compared to HC. In detail, 5/40 acylcarnitines as well as 10/42 amino acids and biogenic amines were mainly increased in AS, whereas 29/90 glycerophospholipids and 6/15 sphingomyelins were mainly reduced. In the post-TAVR group, 10.1% (n = 19) of metabolites showed significant differences when compared to pre-TAVR. Moreover, we found nine metabolites revealing reversible concentration levels. Correlation with clinically important parameters revealed strong correlations between sphingomyelins and cholesterol (r = 0.847), acylcarnitines and brain natriuretic peptide (r = 0.664) and showed correlation of acylcarnitine with an improvement of left ventricular (LV) ejection fraction (r = - 0.513) and phosphatidylcholines with an improvement of LV mass (r = - 0.637). CONCLUSION: Metabolic profiling identified significant and reversible changes in circulating metabolites of patients with AS. The correlation of circulating metabolites with clinical parameters supports the use of these data to identify novel diagnostic as well as prognostic markers for disease screening, pathophysiological studies as well as patient surveillance.
Authors: Luise Gaede; Johannes Blumenstein; Christoph Liebetrau; Oliver Dörr; Won-Keun Kim; Holger Nef; Oliver Husser; Jan Gülker; Albrecht Elsässer; Christian W Hamm; Stephan Achenbach; Helge Möllmann Journal: Clin Res Cardiol Date: 2019-06-24 Impact factor: 5.460
Authors: Evasio Pasini; Roberto Aquilani; Francesco S Dioguardi; Giuseppe D'Antona; Mihai Gheorghiade; Heinrich Taegtmeyer Journal: Am J Cardiol Date: 2008-06-02 Impact factor: 2.778
Authors: Eberhard Grube; Nicolas M Van Mieghem; Sabine Bleiziffer; Thomas Modine; Johan Bosmans; Ganesh Manoharan; Axel Linke; Werner Scholtz; Didier Tchétché; Ariel Finkelstein; Ramiro Trillo; Claudia Fiorina; Antony Walton; Christopher J Malkin; Jae K Oh; Hongyan Qiao; Stephan Windecker Journal: J Am Coll Cardiol Date: 2017-08-15 Impact factor: 24.094
Authors: Wolfgang Drobnik; Gerhard Liebisch; Franz-Xaver Audebert; Dieter Frohlich; Thomas Gluck; Peter Vogel; Gregor Rothe; Gerd Schmitz Journal: J Lipid Res Date: 2003-01-16 Impact factor: 5.922
Authors: Sammy Elmariah; Laurie A Farrell; Maureen Daher; Xu Shi; Michelle J Keyes; Carolyn H Cain; Eugene Pomerantsev; Gus J Vlahakes; Ignacio Inglessis; Jonathan J Passeri; Igor F Palacios; Caroline S Fox; Eugene P Rhee; Robert E Gerszten Journal: J Am Heart Assoc Date: 2016-03-15 Impact factor: 5.501
Authors: Miriam Puls; Bo Eric Beuthner; Rodi Topci; Anja Vogelgesang; Annalen Bleckmann; Maren Sitte; Torben Lange; Sören Jan Backhaus; Andreas Schuster; Tim Seidler; Ingo Kutschka; Karl Toischer; Elisabeth Maria Zeisberg; Claudius Jacobshagen; Gerd Hasenfuß Journal: Eur Heart J Date: 2020-05-21 Impact factor: 29.983